Provided by Tiger Trade Technology Pte. Ltd.

Alpha Tau Medical

14.92
+0.56003.90%
Post-market: 14.950.0300+0.20%19:48 EDT
Volume:626.16K
Turnover:9.28M
Market Cap:1.38B
PE:-14.19
High:15.02
Open:14.57
Low:14.40
Close:14.36
52wk High:15.02
52wk Low:3.06
Shares:92.33M
Float Shares:63.79M
Volume Ratio:1.47
T/O Rate:0.98%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0517
EPS(LYR):-0.5300
ROE:-141.68%
ROA:-25.71%
PB:31.27
PE(LYR):-28.15

Loading ...

Nano Dimension Appoints Oramed CEO Nadav Kidron to Board to Chair Strategy, Capital Allocation Committee

Reuters
·
Aug 17

Nano Dimension Appoints Nadav Kidron to Board of Directors to Chair Strategy and Capital Allocation Committee

THOMSON REUTERS
·
Aug 17

Top Executive Makes Notable Move With Alpha Tau Medical Stock

TIPRANKS
·
Aug 13

Alpha Tau Medical CFO Raphi Levy Disposes of 17,730 Shares for $248,037.74

Reuters
·
Aug 13

Alpha Tau Medical is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Aug 11

Alpha Tau price target raised to $16 from $15 at H.C. Wainwright

TIPRANKS
·
Aug 11

Alpha Tau Medical Ltd. : H.c. Wainwright Raises Target Price to $16 from $15

THOMSON REUTERS
·
Aug 11

U.S. Research Roundup-Accendra Health, Celestica, Sionna Therapeutics

Reuters
·
Aug 11

Alpha Tau Medical Updates Investors With H1 2026 Financials in New Form 6-K Filing

TIPRANKS
·
Aug 11

Alpha Tau Medical Q2 EPS $(0.50) Misses $(0.14) Estimate

Benzinga Earnings
·
Aug 11

Alpha Tau FY26 H1 Net Loss More than Doubled to $68.8 Million

Reuters
·
Aug 11

Press Release: Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Dow Jones
·
Aug 11

Alpha Tau Medical Registers for Dual Listing on Tel Aviv Stock Exchange, Keeps NASDAQ Listing

Reuters
·
Aug 10

Alpha Tau Medical (DRTS) Is Down 7.7% After Reporting 100% Response In Alpha DaRT Combo Study

Simply Wall St.
·
Jul 26

Alpha Tau Medical Price Target Maintained with a $15.00/share by HC Wainwright & Co.

Dow Jones
·
Jul 23

Alpha Tau Medical Notifies Availability of Press Release on Alpha Dart-pembrolizumab Head and Neck Cancer Data

Reuters
·
Jul 21

Alpha Tau Medical - no Serious Alpha Dart-associated Adverse Events; Only Two Grade 1 Events Reported

THOMSON REUTERS
·
Jul 21

Alpha Tau Medical - Median Overall Survival 18.2 Months, Median Progression-free Survival 5.4 Months with Alpha Dart Plus Pembrolizumab

THOMSON REUTERS
·
Jul 21

Alpha Tau Medical Price Target Maintained with a $15.00/share by HC Wainwright & Co.

Dow Jones
·
Jul 16

Analysts’ Top Healthcare Picks: Alpha Tau Medical Ltd (DRTS), Abbott Laboratories (ABT)

TIPRANKS
·
Jul 16